Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) cell lines with EGFR-TKIs decreased the expression of PD-1 and PD-L1 by inhibiting the NF-κB pathway [109,110,111]. Here, EGFR is linked to non-small cell lung carcinoma.